Zentalis Pharmaceuticals Investor Presentation — August 2021

Document content

Creating Differentiated Therapies to Improve

the Lives of Cancer PatientsForward -Looking Statements and Disclaimer

2Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including or al commentary that accompanies this presentation) contains forward -looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this prese ntation that do not relate to matters of historical fact should be considered

forward -looking statements, including without limitation statements regarding our future financial or business performance, plan s, prospects, trends or strategies, objectives of management,

competition and other financial and business matters, the potential, safety, efficacy, and regulatory and clinical progress o f our current and prospective product candidates, plans and timing for the

initiation of and release of data from our clinical trials and our ability to meet other key milestones, planned preclinical activities, our current and prospective collaborations, the estimated size of the

market for our product candidates, and the timing and success of our development and commercialization of our anticipated pro duct candidates and the market acceptance thereof are forward -looking

statements, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estim ate,” “may,” “should,” “anticipate” and similar statements of a future or

forward -looking nature. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results,

performance or achievements to be materially different from any future results, performance or achievements expressed or impl iedby the forward -looking statements, including, but not limited to, the

following: the outbreak of the novel coronavirus disease, COVID -19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our

limited operating history, which may make it difficult to evaluate our current business and predict our future success and vi ability; we have and expect to continue to incur significant losses; our need for

additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; fail ureto identify additional product candidates and develop or commercialize

marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cau se delays or other adverse consequences; risks relating to the regulatory